ALLO
Allogene Therapeutics, Inc.
There isn't enough reported data to score ALLO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ALLO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALLO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALLO PE Valuation
ALLO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ALLO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ALLO's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ALLO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$0.34 |
| Q2 2026 | -$0.67 | +$0.43 |
| Q1 2026 | -$0.77 | +$0.45 |
| Q4 2025 | -$0.87 | +$0.45 |
| Q3 2025 | -$0.97 | +$0.57 |
| Q2 2025 | -$1.10 | +$0.49 |
| Q1 2025 | -$1.22 | +$0.55 |
| Q4 2024 | -$1.32 | +$0.75 |
ALLO is still losing money, but far less than before: $0.63 per share over the past year, against $2.45 at its worst in mid-2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ALLO on earnings quality, reporting a profit while its opponent remains loss making.
ALLO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2024 | $22K | -58% |
| Q4 2023 | $21K | -55% |
| Q3 2023 | $43K | -12% |
| Q2 2023 | $44K | -49% |
| Q1 2023 | $52K | -15% |
| Q4 2022 | $47K | -7.8% |
| Q3 2022 | $49K | 0% |
| Q2 2022 | $86K | +95% |
ALLO's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1011% | N/A |
| Q1 2024 | -315927% | -125408 points |
| Q4 2023 | -405281% | -200230 points |
| Q3 2023 | -146453% | +21891 points |
| Q2 2023 | -182995% | -93933 points |
| Q1 2023 | -190519% | -59385 points |
| Q4 2022 | -205051% | -60163 points |
| Q3 2022 | -168345% | -9835 points |
ALLO's operating margin was −1011% last quarter, up 181984 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ALLO on profitability, with a higher operating margin.
ALLO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$36.1M | -$6.2M |
| Q2 2026 | -$32.1M | +$6.9M |
| Q1 2026 | -$12.9M | +$40.1M |
| Q4 2025 | -$27.6M | +$9.4M |
| Q3 2025 | -$29.9M | +$14.6M |
| Q2 2025 | -$39.1M | +$24.5M |
| Q1 2025 | -$53M | +$2.9M |
| Q4 2024 | -$37M | +$16.9M |
ALLO has burned cash in almost every quarter: −$109M over the past year, against −$159M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ALLO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALLO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.2% | +17.2M shares |
| 1 year | +56% | +124M shares |
| 3 years | +106% | +178M shares |
| 5 years | +153% | +209M shares |
| Available history | +242% | +245M shares |
ALLO has 346M diluted shares, up 56% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ALLO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ALLO Net Leverage
ALLO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ALLO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.2 | Oversold |
| Stochastic | 2.4 | Oversold |
ALLO's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ALLO PE vs Healthcare Sector
ALLO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ALLO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 35% below |
| 20 week MA | $1.67 | 50% below |
| 50 week MA | $1.86 | 55% below |
| 100 week MA | $1.66 | 50% below |
| 200 week MA | $2.76 | 70% below |
ALLO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ALLO on trend strength, trading above more of its moving averages.
ALLO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.3 | $27.3 | +3.8% |
| 2021 | $27.3 | $15.7 | -43% |
| 2022 | $15.7 | $5.96 | -62% |
| 2023 | $5.96 | $3.21 | -46% |
| 2024 | $3.21 | $2.19 | -32% |
| 2025 | $2.19 | $1.38 | -37% |
| 2026 YTD | $1.38 | $0.83 | -40% |
ALLO has finished five years in a row lower, and it's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ALLO on returns for 2026, with the stronger performance.